Get the Stockscreener App
16.04
1.71%
0.27
After Hours:
15.97
-0.07
-0.44%
Aurinia Pharmaceuticals Inc stock is traded at $16.04, with a volume of 928.33K.
It is up +1.71% in the last 24 hours and up +2.75% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$15.77
Open:
$15.86
24h Volume:
928.33K
Relative Volume:
0.89
Market Cap:
$2.08B
Revenue:
$283.06M
Net Income/Loss:
$287.20M
P/E Ratio:
7.7223
EPS:
2.0771
Net Cash Flow:
$135.69M
1W Performance:
+0.00%
1M Performance:
+2.75%
6M Performance:
+11.00%
1Y Performance:
+94.19%
1-Day Range:
$15.67
$16.11
1-Week Range:
$14.83
$16.11
52-Week Range:
$7.285
$16.88
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
16.04 | 2.05B | 283.06M | 287.20M | 135.69M | 2.0771 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
MSN Money - MSN
Pharma Co. Investor Sues Over Misleading Aurinia Deal - Law360
Short Interest in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Decreases By 15.7% - MarketBeat
AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) Screens Strong on Minervini Trend Template and High Growth Momentum - ChartMill
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
AUPH Stock Price, Quote & Chart | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
Kezar Life Sciences (NASDAQ: KZR) details Aurinia tender offer, pay and ownership - Stock Titan
Aurinia earnings on deck: Can new leadership sustain growth? By Investing.com - Investing.com India
Aurinia earnings on deck: Can new leadership sustain growth? - Investing.com
Kezar Life Sciences shares surge after Aurinia announces acquisition - MSN
Aruinia discloses FDA information request on Lupkynis amid top regulator’s exit - MSN
Can Aurinia (AUPH) Run Higher on Rising Earnings Estimates? - MSN
Aurinia Pharmaceuticals acquiring Kezar Life Sciences - MSN
AUPH News | AURINIA PHARMACEUTICALS INC (NASDAQ:AUPH) - ChartMill
FDA Turmoil Spills Over To Aurinia Pharma As Lawsuit Targets Ex-Drug Review Chief — Retail Traders Cry ‘Stock Manipulation’ - MSN
How (AUPH) Movements Inform Risk Allocation Models - Stock Traders Daily
Aurinia Pharmaceuticals stock hits 52-week high at $16.72 By Investing.com - Investing.com India
Aurinia Pharmaceuticals stock hits 52-week high at $16.72 - Investing.com Australia
Aurinia Pharmaceuticals (NASDAQ:AUPH) Hits New 1-Year HighStill a Buy? - MarketBeat
Aurinia (NASDAQ: AUPH) details 2026 virtual AGM, auditor and say-on-pay - Stock Titan
Aurinia (AUPH) Stock: Risk Exposure (Grinds Higher) 2026-04-18Viral Momentum Stocks - Cổng thông tin điện tử tỉnh Lào Cai
Aurinia (AUPH) Stock Breakout Watch (-1.37%) 2026-04-16Risk Analysis - UBND thành phố Hải Phòng
Tudor Investment Corp ET AL Buys Shares of 65,964 Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
How activist investor Kevin Tang finally landed the Bay Area company that got away from him - The Business Journals
Aurinia Pharmaceuticals (NASDAQ:AUPH) Sets New 12-Month HighHere's What Happened - MarketBeat
Trading Systems Reacting to (AUPH) Volatility - Stock Traders Daily
Aurinia to Acquire Kezar (NASDAQ: KZR) for $6.955 Cash plus CVR - Stock Titan
Ideas Watch: Is Aurinia Pharmaceuticals Inc gaining market sharePortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Guidance Update: Does Aurinia Pharmaceuticals Inc stock have upside surprise potentialBond Market & Real-Time Volume Analysis Alerts - baoquankhu1.vn
Aurinia to buy Kezar (KZR) for $6.955/Share plus CVR (7.39M shares) - Stock Titan
Dow Update: Whats the profit margin of Aurinia Pharmaceuticals Inc2026 Summary & Detailed Earnings Play Alerts - baoquankhu1.vn
Proxy StatementNotice of Shareholders Meeting (preliminary) (pre 14a) - ADVFN
Ritholtz Wealth Management Acquires 174,301 Shares of Aurinia Pharmaceuticals Inc $AUPH - MarketBeat
AUPHAurinia Announces Results of Annual General Meeting - ADVFN
RSI Check: Can Aurinia Pharmaceuticals Inc grow without external fundingDip Buying & Short-Term High Return Ideas - baoquankhu1.vn
Downgrade Watch: Why is Aurinia Pharmaceuticals Inc stock going up2026 Geopolitical Influence & Weekly Setup with High ROI Potential - baoquankhu1.vn
Stock Analysis: Will Aurinia Pharmaceuticals Inc benefit from government policyEarnings Risk Report & Risk Managed Trade Strategies - baoquankhu1.vn
7MM Systemic Lupus Erythematosus and Lupus Nephritis Drug Market Analysis & Forecast 2024-2034: Future SLE and LN Players Competition, High Unmet Need for Steroid-sparing Treatments - GlobeNewswire Inc.
Aurinia Pharmaceuticals Acquisition Of Kezar Reshapes Autoimmune Growth And Risks - Sahm
AUPH Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):